NASDAQ:CLDXCelldex Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Celldex Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $11.04 +0.75 (+7.29 %) (As of 08/3/2020 02:22 PM ET) Add Compare Share Today's Range$10.35Now: $11.04▼$11.1950-Day Range$2.99MA: $11.05▼$13.4152-Week Range$1.50Now: $11.04▼$13.91Volume19,353 shsAverage Volume723,166 shsMarket Capitalization$249.06 millionP/E RatioN/ADividend YieldN/ABeta3.31 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Celldex Therapeutics, Inc. engages in the research, development, and commercialization of immunotherapies and other targeted biologics. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingCelldex Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.00, Celldex Therapeutics has a potential upside of 58.1% from its current price of $10.75.Amount of Analyst CoverageCelldex Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.1 Community Rank Outperform VotesCelldex Therapeutics has received 566 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCelldex Therapeutics has received 349 “underperform” votes. (Add your “underperform” vote.)Community SentimentCelldex Therapeutics has received 61.86% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Celldex Therapeutics and other stocks. Vote “Outperform” if you believe CLDX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CLDX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCelldex Therapeutics does not currently pay a dividend.Dividend GrowthCelldex Therapeutics does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Celldex Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $126,778.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.40% of the stock of Celldex Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 17.61% of the stock of Celldex Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Celldex Therapeutics are expected to decrease in the coming year, from ($2.41) to ($2.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Celldex Therapeutics is -3.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Celldex Therapeutics is -3.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCelldex Therapeutics has a P/B Ratio of 1.84. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.92 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Diagnostic substances Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:CLDX Previous Symbol CUSIP15117B10 CIK744218 Webwww.celldex.com Phone908-200-7500Debt Debt-to-Equity Ratio0.03 Current Ratio5.12 Quick Ratio5.12Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3.57 million Price / Sales69.77 Cash FlowN/A Price / Cash FlowN/A Book Value$5.83 per share Price / Book1.89Profitability EPS (Most Recent Fiscal Year)($3.28) Net Income$-50,880,000.00 Net Margins-948.81% Return on Equity-47.60% Return on Assets-36.32%Miscellaneous Employees133 Outstanding Shares22,560,000Market Cap$249.06 million Next Earnings Date8/5/2020 (Estimated) OptionableOptionable $11.04 +0.75 (+7.29 %) (As of 08/3/2020 02:22 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CLDX News and Ratings via Email Sign-up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter. Celldex Therapeutics (NASDAQ:CLDX) Frequently Asked Questions How has Celldex Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Celldex Therapeutics' stock was trading at $2.03 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CLDX stock has increased by 443.8% and is now trading at $11.04. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Celldex Therapeutics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celldex Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Celldex Therapeutics. When is Celldex Therapeutics' next earnings date? Celldex Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Celldex Therapeutics. How were Celldex Therapeutics' earnings last quarter? Celldex Therapeutics, Inc. (NASDAQ:CLDX) issued its earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.71) by $0.02. The biopharmaceutical company earned $2.73 million during the quarter, compared to the consensus estimate of $1.28 million. Celldex Therapeutics had a negative net margin of 948.81% and a negative return on equity of 47.60%. View Celldex Therapeutics' earnings history. When did Celldex Therapeutics' stock split? How did Celldex Therapeutics' stock split work? Shares of Celldex Therapeutics reverse split on the morning of Monday, February 11th 2019. The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 8th 2019. An investor that had 100 shares of Celldex Therapeutics stock prior to the reverse split would have 7 shares after the split. What price target have analysts set for CLDX? 2 brokers have issued 1-year price objectives for Celldex Therapeutics' stock. Their forecasts range from $16.00 to $18.00. On average, they anticipate Celldex Therapeutics' stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 54.0% from the stock's current price. View analysts' price targets for Celldex Therapeutics. Has Celldex Therapeutics been receiving favorable news coverage? Media stories about CLDX stock have trended negative on Monday, according to InfoTrie. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Celldex Therapeutics earned a media sentiment score of -2.9 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. View the latest news about Celldex Therapeutics. Who are some of Celldex Therapeutics' key competitors? Some companies that are related to Celldex Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Novavax (NVAX). View all competitors. What other stocks do shareholders of Celldex Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Celldex Therapeutics investors own include Opko Health (OPK), Gilead Sciences (GILD), Corbus Pharmaceuticals (CRBP), ACADIA Pharmaceuticals (ACAD), Precigen (PGEN), Micron Technology (MU), Synergy Pharmaceuticals (SGYP), Dynavax Technologies (DVAX), bluebird bio (BLUE) and Exelixis (EXEL). Who are Celldex Therapeutics' key executives? Celldex Therapeutics' management team includes the following people: Anthony S. Marucci, President, Chief Executive Officer & DirectorSam Martin, CFO, Secretary, Treasurer & Senior Vice PresidentTibor Keler, Chief Scientific Officer & Executive VPElizabeth Crowley, Chief Product Development Officer & Senior VPRonald A. Pepin, Chief Business Officer & Senior Vice President What is Celldex Therapeutics' stock symbol? Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX." Who are Celldex Therapeutics' major shareholders? Celldex Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include TSP Capital Management Group LLC (1.63%), Creative Planning (0.16%) and Raymond James Financial Services Advisors Inc. (0.07%). Company insiders that own Celldex Therapeutics stock include Anthony S Marucci, Diane C Young, James J Marino, Margo Heath-Chiozzi, Samuel Bates Martin and Tibor Keler. View institutional ownership trends for Celldex Therapeutics. Which major investors are selling Celldex Therapeutics stock? CLDX stock was sold by a variety of institutional investors in the last quarter, including TSP Capital Management Group LLC, and Raymond James Financial Services Advisors Inc.. View insider buying and selling activity for Celldex Therapeutics. Which major investors are buying Celldex Therapeutics stock? CLDX stock was acquired by a variety of institutional investors in the last quarter, including Creative Planning. Company insiders that have bought Celldex Therapeutics stock in the last two years include Anthony S Marucci, Diane C Young, James J Marino, Margo Heath-Chiozzi, Samuel Bates Martin, and Tibor Keler. View insider buying and selling activity for Celldex Therapeutics. How do I buy shares of Celldex Therapeutics? Shares of CLDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Celldex Therapeutics' stock price today? One share of CLDX stock can currently be purchased for approximately $11.04. How big of a company is Celldex Therapeutics? Celldex Therapeutics has a market capitalization of $249.06 million and generates $3.57 million in revenue each year. The biopharmaceutical company earns $-50,880,000.00 in net income (profit) each year or ($3.28) on an earnings per share basis. Celldex Therapeutics employs 133 workers across the globe. What is Celldex Therapeutics' official website? The official website for Celldex Therapeutics is www.celldex.com. How can I contact Celldex Therapeutics? Celldex Therapeutics' mailing address is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. The biopharmaceutical company can be reached via phone at 908-200-7500 or via email at [email protected] This page was last updated on 8/3/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
